Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16920345 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006317 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL6374726 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006306 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL5802417 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006316 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7449326 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862746 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862743 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| SCHEMBL8881468 | 0.93 | CTSC (0.40) | CTSCGRIK1AGTR2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLYPHOR AG (CH) | 2023-09-12 | — | — | US | disclosed |
| CN-115093463-A | Beta-hairpin peptidomimetics | 波利弗尔股份公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-3201219-B1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| CN-105324390-B | Beta-hairpin peptidomimetics | 波利弗尔股份公司 | 2021-10-19 | — | — | CN | disclosed |
| CN-105849119-B | Beta-hairpin peptidomimetics | 波利弗尔股份公司 | 2021-01-19 | — | — | CN | disclosed |
| US-10829520-B2 | Beta-hairpin peptidomimetics | POLYPHOR AG (CH) | 2020-11-10 | — | — | US | disclosed |
| US-20200231629-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2020-07-23 | — | — | US | disclosed |
| US-10654897-B2 | β-hairpin peptidomimetics | POLYPHOR AG (CH) | 2020-05-19 | — | — | US | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-0797577-B1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMA (CA) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| US-5703072-A | TREATMENT OF SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS (CA) | 1997-12-30 | — | — | US | disclosed |
| EP-0804465-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0797577-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | Allelix Biopharmaceuticals Inc. (CA) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231629-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | BET1, BACH1, POLL | CTSC 1055/4885GRIK1 2981/4885AGTR2 2129/4885 |
| US-10654897-B2 | β-hairpin peptidomimetics | BACE1, C1S, POLL | CTSC 1153/4885GRIK1 3438/4885AGTR2 1800/4885 |
| US-10829520-B2 | Beta-hairpin peptidomimetics | POLQ, POLL, POLM | CTSC 1598/4885GRIK1 4041/4885AGTR2 2505/4885 |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLL, BACE1, C1S | CTSC 1176/4885GRIK1 3418/4885AGTR2 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.